Filter posts

What Parallel Review Means for Manufacturers

By Stephen Rothenberg, J.D. and Matt Levy, J.D., Numerof & Associates, Inc. (NAI) Currently, the …

Managing in a Cost-Constrained Environment

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at …

Let's Get PDUFA V Approved, Fast

By Marc Boutin, JD, Executive Vice President and Chief Operating Officer, National Health Council At …

2012: A Critical Year for Biotechnology

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce …

The Ethics of Global Clinical Trials

By Dr. Russell Medford, Salutria Pharmaceuticals Recent reports have raised concerns about how clinical trials are …

Is Animal Biotechnology Progressing?

By David Edwards, PhD Director, Animal Biotechnology, BIO One year ago, I was pleased to …

FDA: How can we improve it?

By Stephen Sherwin, Former Chairman of BIO As Congress and the President work together to hammer out …

A Center for Advancing Translational Science can spur new therapies

Sometimes, spurring the development of new drugs and therapies can be like trying to a …

If Biotech Builds…Will Financers Come?

Angie Drakulich from PharmaTech Talk writes: In many countries, it’s easy to get the health …

FDA: A Cornerstone of America’s Economic Future

By Nancy Bradish Myers, JD, President, Alliance for a Stronger FDA For close to 20 …